Back
Speaker illustration

Doctor Silvia Cantoni

R&D Chiesi Farmaceutici S.P.A., Parma (Italy)

Member of:

European Society of Cardiology

Presentations

The selective rho kinase inhibitor trans-6-((4-aminocyclohexyl)amino)-5-fluoro-2-methoxynicotinamide ameliorates monocrotaline-induced pulmonary hypertension

Event: ESC Congress 2017

Topic: Chronic pulmonary hypertension

Session: Understanding the pulmonary circulation

Access
Like
Thumbnail

Hemodynamic and anti-remodelling effect of the rho kinase inhibitor y-27632 in monocrotaline pulmonary arterial hypertension rat model

Event: ESC Congress 2016

Topic: Chronic pulmonary hypertension

Session: Basic mechanisms in pulmonary hypertension

Access
Like
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources